129 related articles for article (PubMed ID: 3839994)
1. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer.
Bailey MJ; Smith IE
Anticancer Res; 1985; 5(4):419-22. PubMed ID: 3839994
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice.
Sordillo PP; Helson L; Lesser M
Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
6. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
7. Effect of five antineoplastic agents on tumor xenografts with different growth rates.
Mattern J; Wayss K; Volm M
J Natl Cancer Inst; 1984 Jun; 72(6):1335-9. PubMed ID: 6587154
[TBL] [Abstract][Full Text] [Related]
8. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Man S; Munoz R; Kerbel RS
Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
[TBL] [Abstract][Full Text] [Related]
9. [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Ogawa M
Gan To Kagaku Ryoho; 1986 May; 13(5):1829-36. PubMed ID: 3754711
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Amrein PC; Coleman M; Richards F; Poulin RF; Bernhardt B; Ginsberg SJ; Green MR; Morrison A; Cortes E; Kiang D; Weinberg V; Wood WC
Cancer Treat Rep; 1982 May; 66(5):1211-3. PubMed ID: 6896294
[No Abstract] [Full Text] [Related]
12. m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Weiss RB; Charles LM; Macdonald JS
Cancer Clin Trials; 1980; 3(3):203-9. PubMed ID: 7002337
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic response of three human tumor lines maintained in immune-suppressed mice.
Kopper L; Steel GG
Cancer Res; 1975 Oct; 35(10):2704-13. PubMed ID: 1157045
[TBL] [Abstract][Full Text] [Related]
14. [Mitoxantrone in a combination regimen in advanced breast cancer].
Hausmaninger H
Wien Med Wochenschr; 1985 Dec; 135(23-24):594-7. PubMed ID: 4096006
[TBL] [Abstract][Full Text] [Related]
15. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
Tannir N; Spitzer G; Schell F; Legha S; Zander A; Blumenschein G
Cancer Treat Rep; 1983 Jun; 67(6):599-600. PubMed ID: 6344995
[No Abstract] [Full Text] [Related]
17. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
18. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
19. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study.
Smyth JF; Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT
Semin Oncol; 1984 Sep; 11(3 Suppl 1):15-8. PubMed ID: 6484578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
